Role of new agents in the treatment of colorectal cancer

Surgical Oncology

Volumn 13, Issue 2-3, 2004, Pages 75-81

  Köhne, Claus Henning ^a   Bruce, Caroline ^b   Folprecht, Gunnar ^c   Audisio, Riccardo ^b,d  

^a KLINIKUM OLDENBURG   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c WHISTON HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Capecitabine; Cetuximab; Chemotherapy; Colorectal cancer; Irinotecan; Oxaliplatin; UFT

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; ATROPINE; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; EMD 7200; ENIURACIL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; NEW DRUG; OXALIPLATIN; PROTEIN TYROSINE KINASE INHIBITOR; ROFECOXIB; UNCLASSIFIED DRUG; URACIL; VASCULOTROPIN INHIBITOR;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INFUSION; DRUG METABOLISM; DRUG RESPONSE; DRUG SCREENING; DRUG TARGETING; DRUG UTILIZATION; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; METASTASIS; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 9644303264     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2004.09.004     Document Type: Article

References (51)

1. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. Journal of Clinical Oncology 1992; 10: 896-903.
2. M. Miwa, M. Ura, M. Nishida, N. Sawada, T. Ishikawa, K. Mori, N. Shimma, I. Umeda, and H. Ishitsuka Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue European Journal of Cancer 34 1998 1274 1281
3. M. Mackean, A. Planting, C. Twelves, J. Schellens, D. Allman, B. Osterwalder, B. Reigner, T. Griffin, S. Kaye, and J. Verweij Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer Journal of Clinical Oncology 16 1998 2977 2985
4. E. Van Cutsem, M. Findlay, B. Osterwalder, W. Kocha, D. Dalley, R. Pazdur, J. Cassidy, L. Dirix, C. Twelves, D. Allman, J.F. Seitz, J. Scholmerich, H.U. Burger, and J. Verweij Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer results of a randomized phase II study Journal of Clinical Oncology 18 2000 1337 1345
5. R.L. Schilsky, J. Levin, W.H. West, A. Wong, B. Colwell, M.P. Thirlwell, R.H. Ansari, W.N. Bell, R.L. White, B.B. Yates, P.V. McGuirt, and R. Pazdur Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer Journal of Clinical Oncology 20 2002 1519 1526
6. E. Van Cutsem, J. Sorensen, J. Cassidy, F. Daniel, P. Harper, N. Bailey, M. Peachey, and M. Sommerville International phase III study of oral eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC) Proceedings of the American Society of Clinical Oncology 20 2001 131a
7. E. Van Cutsem, C. Twelves, J. Cassidy, D. Allman, E. Bajetta, M. Boyer, R. Bugat, M. Findlay, S. Frings, M. Jahn, J. McKendrick, B. Osterwalder, G. Perez-Manga, R. Rosso, P. Rougier, W.H. Schmiegel, J.F. Seitz, P. Thompson, J.M. Vieitez, C. Weitzel, and P. Harper Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer results of a large phase III study Journal of Clinical Oncology 19 2001 4097 4106
8. P.M. Hoff, R. Ansari, G. Batist, J. Cox, W. Kocha, M. Kuperminc, J. Maroun, D. Walde, C. Weaver, E. Harrison, H.U. Burger, B. Osterwalder, A.O. Wong, and R. Wong Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer results of a randomized phase III study Journal of Clinical Oncology 19 2001 2282 2292
9. J. Carmichael, T. Popiela, D. Radstone, S. Falk, M. Borner, A. Oza, T. Skovsgaard, S. Munier, and C. Martin Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer Journal of Clinical Oncology 20 2002 3617 3627
10. J.Y. Douillard, P.M. Hoff, J.R. Skillings, P. Eisenberg, N. Davidson, P. Harper, M.D. Vincent, B.C. Lembersky, S. Thompson, A. Maniero, and S.E. Benner Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer Journal of Clinical Oncology 20 2002 3605 3616
11. C.H. Köhne, E. Van Cutsem, J. Wils, C. Bokemeyer, M. El-Sarafi, M. Lutz, M. Lorenz, P. Reichardt, H. Rückle-Lanz, N. Frickhofen, R. Fuchs, H-G. Mergenthaler, T. Langenbuch, A. Vandebroeck, J-Y. Douillard, U. Vanhoefer, R. Voigtmann, E. Mitry, L. Müller, B. Baron, N.G. Vanacker, and B. Nordlinger Weekly high dose infusional 5-FU plus folinic acid (FA) with or without irinotecan (IRI) in metastatic colorectal cancer (MCRC) interim safety results of EORTC study 40986 Proceedings of the American Society of Clinical Oncology 21 2002 134a
12. J.Y. Douillard, D. Cunningham, A.D. Roth, M. Navarro, R.D. James, P. Karasek, P. Jandik, T. Iveson, J. Carmichael, M. Alakl, G. Gruia, L. Awad, and P. Rougier Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer a multicentre randomised trial Lancet 355 2000 1041 1047
13. L.B. Saltz, J.V. Cox, C. Blanke, L.S. Rosen, L. Fehrenbacher, M.J. Moore, J.A. Maroun, S.P. Ackland, P.K. Locker, N. Pirotta, G.L. Elfring, and L.L. Miller Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group [see comments] New England Journal of Medicine 343 905 343, 2000 914
14. P. Rougier, C.E. Van, E. Bajetta, N. Niederle, K. Possinger, R. Labianca, M. Navarro, R. Morant, H. Bleiberg, J. Wils, L. Awad, P. Herait, and C. Jacques Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Lancet 352 1998 1407 1412 [published erratum appeared in Lancet 1998;352(9140):1634.]
15. E. Raymond, C. Buquet-Fagot, S. Djelloul, J. Mester, E. Cvitkovic, P. Allain, C. Louvet, and C. Gespach Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers Anticancer Drugs 8 1997 876 885
16. M.L. Rothenberg, A.M. Oza, B. Burger, J. Berlin, J. Marshall, R.K. Ramanathan, S. Gupta, C. Garay, and D.G. Haller Phase III trial of bolus+infusional 5-FU/leucovorin vs oxaliplatin vs the combination in patients with recurrent metastatic colorectal cancer following irinotecan, bolus 5-FU, and leucovorin interim results Annals of Oncology 13 2002 2
17. A. de Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, C. Boni, H. Cortes-Funes, A. Cervantes, G. Freyer, D. Papamichael, N. Le Bail, C. Louvet, D. Hendler, F. de Braud, C. Wilson, F. Morvan, and A. Bonetti Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer Journal of Clinical Oncology 18 2000 2938 2947
18. R.M. Goldberg, R.F. Morton, D.J. Sargent, C.S. Fuchs, R.K. Ramanathan, S.K. Williamson, and B.P. Findlay N9741 oxaliplatin (oxal) or CPT-11+5-fluorouracil (5-FU)/leucovorin (LV) or oxal+CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study Proceedings of the American Society of Clinical Oncology 21 2002 128a
19. C. Tournigand, C. Louvet, E. Quinaux, T. Andre, G. Lledo, M. Flesh, G. Ganem, B. Landi, F. Colin, C. Denet, D. Mery-Mignard, M. Risse, M. Buyse, and A. De-Gramont FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC) final results of a phase III study Proceedings of the American Society of Clinical Oncology 20 2001 124a
20. S. Giacchetti, M. Itzhaki, G. Gruia, R. Adam, R. Zidani, F. Kunstlinger, S. Brienza, E. Alafaci, F. Bertheault-Cvitkovic, C. Jasmin, M. Reynes, H. Bismuth, J.L. Misset, and F. Levi Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery Annals of Oncology 10 1999 663 669
21. M. Gil-Delgado, G. Bastian, F. Guinet, E. Antoine, F.L. Cajfinger, M.A. Rocher, D. Coeffic, J.P. Spano, S. Taillibert, H. Bismuth, and D. Khayat Final results of oxaliplatin (LOHP)+irinotecan (CPT11) and FU-FOL (LV5 FU2) combination and pharmacokinetic (PK) analysis in advanced colorectal cancer (ACRC) patients (pts) Proceedings of the American Society of Clinical Oncology 20 2001 140a
22. M. Ychou, B. Nordlinger, F. Quenet, M.L. Rivoire, F. Desseigne, S. Negrier, P. Rougier, M. Giovannini, J.R. Delpero, G. Houvenaeghel, R. Bugat, J.P. Delord, F. Lazorthes, C. Couteau, O. Ferment, and E. Chaboisseau CPT-11/L-OHP/5-FU/ LV combination before liver surgery in patients with not optimally resectable colorectal cancer liver metastases methodology and preliminary results, phase II study Proceedings of the American Society of Clinical Oncology 21 2002 162a
23. C.H. Köhne, D. Cunningham, F. Di Costanzo, B. Glimelius, G. Blijham, E. Aranda, W. Scheithauer, P. Rougier, M. Palmer, J. Wils, B. Baron, F. Pignatti, P. Schoffski, S. Micheel, and H. Hecker Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer results of a multivariate analysis of 3825 patients Annals of Oncology 13 2002 308 317
24. J. Tabernero, A.C. Butts, J. Cassidy, T. Conroy, F. de Braud, E. Diaz-Rubio, A. Figer, P. Schoeffski, J. Grossmann, A. Sobrero, C. Twelves, and E. Van Cutsem Capecitabine and oxaliplatin in combination (Xelox) as first line therapy for patients (pts) with metastatic colorectal cancer (MCRC) results of an international multicenter phase II trial Proceedings of the American Society of Clinical Oncology 21 2002 133a
25. M.M. Borner, D. Dietrich, R. Stupp, R. Morant, H. Honegger, M. Wernli, R. Herrmann, B.C. Pestalozzi, P. Saletti, S. Hanselmann, S. Muller, P. Brauchli, M. Castiglione-Gertsch, A. Goldhirsch, and A.D. Roth Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer Jounal of Clinical Oncology 20 2002 1759 1766
26. K. Jordan, A. Grothey, O. Kellner, C. Constantin, G. Dietrich, C. Schlichting, L. Mantovani, H. Kroening, V. Hagen, K. Gutberlet, H. Forstbauer, and H.J. Schmoll Randomized phase II trial of capecitabine plus irinotecan vs capecitabine plus oxaliplatin as first-line therapy in advanced colorectal cancer (ACRC) results of an interim analysis Proceedings of the American Society of Clinical Oncology 21 2002 103b
27. G. Masi, G. Allegrini, R. Danesi, A. di Paolo, S. Cupini, L. Marcucci, E. Pfanner, I. Brunetti, P.F. Conte, M. Del Tacca, and A. Falcone Bi-weekly irinotecan (CPT-11), oxaliplatin (LOHP), leucovorin (LV) and 5-fluorouracil (5-FU) 48 h continuous infusion in advanced colorectal cancer (ACRC) Proceedings of the American Society of Clinical Oncology 21 2002 169a
28. J. Souglakos, D. Mavroudis, S. Kakolyris, C. Kourousis, N. Vardakis, N. Androulakis, S. Agelaki, K. Kalbakis, D. Tsetis, N. Athanasiadis, G. Samonis, and V. Georgoulias Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer a multicenter phase II trial Journal of Clinical Oncology 20 2002 2651 2657
29. C. Aschele, M.L. Friso, S. Pucciarelli, L. Sartor, S. Lonardi, G. De Salvo, G. Fabris, G. da Dalt, R. Ranzato, A. Bruttocao, D. Neri, C. Finco, and S. Monfardini A phase I-II study of weekly oxaliplatin (OXA), 5-fluorouracil (FU) continuous infusion (CI) and preoperative radiotherapy (RT) in locally advanced rectal cancer (LARC) Proceedings of the American Society of Clinical Oncology 21 2002 132a
30. C. Ehrlichman, R.M. Goldberg, J.A. Sloan, J.M. Reid, A.A. Adjei, P. Atherton, A.J. Windebank, and L.J. Hanson Phase I study of the combination of CPT-11/5-FU/leucovorin/oxaliplatin Proceedings of the American Society of Clinical Oncology 21 2002 107a
31. A.D. Roth, Y. Seium, T. Ruhstaller, J. Bauer, C. Soravia, G. Mentha, C. Trembleau, R. Morant, and R. Stupp Oxaliplatine (OXA) combined with irinotecan (CPT-11) and 5-FU/leucovorin (OCFL) in metastatic colorectal cancer (MCRC) a phase I-II study Proceedings of the American Society of Clinical Oncology 21 2002 143a
32. E. Calvo, J.E. Cortes, J. Rodriguez, J. Rebollo, S. Martin-Algarra, J. Garcia-Foncillas, E. Salgado, M. Gonzalez-Cao, J.M. Aramendia, O. Fernandez-Hidalgo, and A. Brugarolas Irinotecan, oxaliplatin plus 5-FU/leucovorin in advanced colorectal cancer Proceedings of the American Society of Clinical Oncology 20 2001 136a
33. F. Lerebours, P. Cottu, H. Hocini, N. Bedairia, A. Bexon, N. Chouaki, M. Espie, and M. Marty Oxaliplatin (OXA), irinotecan (CPT11), and 4-day continuous infusion 5-fluorouracil (CIVFU) every three weeks (Q3W) a phase I study in advanced gastrointestinal tumors Proceedings of the American Society of Clinical Oncology 19 2000 313a
34. G. Rubio, M. Chacon, F. Coppola, J. Martinez, J. Hidalgo, E. Richardet, L. Carranza, S. Sena, K. Vera, C. Martin, and E. Wasserman CPT-11/oxaliplatin (OXA) plus folinic acid (FA)/5-FU bolus (triple combination) an active and feasible combination in metastatic colorectal cancer (CRC) patients (pts) Proceedings of the American Society of Clinical Oncology 21 2002 110b
35. J. Souglakos, N. Ziras, A. Polyos, A. Athanasiadis, S. Kakolyris, and T. Giannakais, Oxaliplatin (1-OHP) combined with irinotecan (CPT-11), leukovarin (LV) and fluoracil (5-FU) compared with irinotecan, leucovorin and fluorouracil as first line treatment for metastatic colorectal cancer prelimary results of a multicenter randomised phase III trial Proceedings of the American Society of Clinical Oncology 23 2004 25
36. C.E. Eberhart, R.J. Coffey, A. Radhika, F.M. Giardiello, S. Ferrenbach, and R.N. DuBois Up-regulation of cyclooxygenase 2 gene expression in human colorectaladenomas and adenocarcinomas Gastroenterology 107 1994 1183 1188
37. H. Sano, Y. Kawahito, R.L. Wilder, A. Hashiramoto, S. Mukai, K. Asai, S. Kimura, H. Kato, M. Kondo, and T. Hla Expression of cyclooxygenase-1 and -2 in human colorectal cancer Cancer Research 55 1995 3785 3789
38. R.N. DuBois, and W.E. Smalley Cyclooxygenase, NSAIDs, and colorectal cancer Journal of Gastroenterology 31 1996 898 906
39. G. Steinbach, P.M. Lynch, R.K. Phillips, M.H. Wallace, E. Hawk, G.B. Gordon, N. Wakabayashi, B. Saunders, Y. Shen, T. Fujimura, L.K. Su, and B. Levin The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis New England Journal of Medicine 342 2000 1946 1952
40. E. Lin, J. Morris, N.K. Chau, C. Crane, R. Wolff, N. Janjan, H. Xiong, M. Delcos, and J.L. Abbruzzese Celecoxib attenuated capecitabine induced hand-and-foot syndrome (HFS) and diarrhea and improved time to tumor progression in metastatic colorectal cancer Proceedings of the American Society of Clinical Oncology 21 2002 138b
41. C.D. Blanke, A. Benson, T. Dragovich, J. Lenz H-, D. Haller, C. Robles, and A. Buchbinder A phase II trial of celecoxib (CX), irinotecan (I), 5-fluorouracil (5-FU), and leucovorin (LCV) in patients (pts) with unresectable or metastatic colorectal cancer (CRC) Proceedings of the American Society of Clinical Oncology 21 2002 127a
42. A. Well Molecules in focus-EGF receptor International Journal of Biochemistry and Cell Biology 31 1999 637 643
43. N.I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Clinical Cancer Research 1 1995 1311 1318
44. L. Saltz, M. Rubin, H. Hochster, N.S. Tchemeydian, H.W. Waksal, M. Needle, and A. LoBuglio Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) Proceedings of the American Society of Clinical Oncology 20 2001 3a
45. L. Saltz, N.J. Meropol, P.J. Loehrer, H.W. Waksal, M. Needle, and R.J. Mayer Single agent IMC-C225 (Erbitux) has activity in CPT-11- refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR) Proceedings of the American Society of Clinical Oncology 21 2002 127a
46. A.H. Rosenberg, P.J. Loehrer, M. Needle, H.W. Waksal, E. Hollywood, L. Ramos, and L.B. Saltz Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5-FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr) Proceedings of the American Society of Clinical Oncology 21 2002 135a
47. M.P. Lutz, P. Schöffski, G. Folprecht, C. Haag, T. Seufferlein, G. Beutel, J.P. Marschner, M. Mueser, A. Harstrick, and C.H. Köhne A phase I/II study of cetuximab (C225) plus irinotecan (CPT-11) and 24 h infusional 5-FU/folinic acid (FA) in the treatment of metastatic colorectal cancer (MCRC) expressing the epidermal growth factor receptor (EGFR) Annals of Oncology 13 2002 73
48. E. Bergsland, H. Hurwitz, L. Fehrenbacher, N.J. Meropol, L. Novotny, J. Gaudreault, G. Lieberman, and F. Kabbinavar A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer Proceedings of the American Society of Clinical Oncology 19 2000 242a
49. Kabbinavar, FI, Schulz J, McClecd M, Patel T, Hamm J, Hecht J, Perrou B, Griffing S, Nelson B, Novotny W. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CDT-11. Proceedings of the American Society of Clinical Oncology 2004 #3516.
50. Chen HX, Mooney M, Boron M, Grochow L, Zwiebel J, Vena D, Mosby K, Grandinetti C, Kaplan RS, TRC Participating Investigators. Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301). Proceedings of the American Association of Clinical Oncology 2004 #3515.
51. Souglakos J, Ziras N, Polyzos A, Athanasiadis A, Kakolyris S, Giannakakis T, Tselepatiotis E, Kalbakis K, Vardakis N, Georgoulias V. Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and fluorouracil (5-FU) compared with irinotecan, leucovorin and fluorouracil as first-line treatment for metastic colorectal cancer (MCC): Preliminary results of a multicenter randomized phase III trail. Proceedings of the American Society of Clinical Oncology 2004 #3532.